NH001 promotes consciousness and improves the functional outcome in patients in a post-traumatic coma, vegetative state or minimally conscious state. The faster the patient recovers consciousness, the better the chances for recovery of functionality.
As a result of trauma, portions of the brain die. During the recovery process, the remaining functional structures of the brain reorganize and take control of functions formerly controlled by the now dead structures. This natural healing is mediated by a process that is referred to as neural plasticity. NH001 aims to provide the right conditions in order to accelerate the neural plasticity process.
NeuroHealing has designed two clinical trials to study the safety and efficacy of NH001 in accelerating the recovery and improving the functional outcome of post TBI vegetative state and minimally conscious state patients. The first clinical trial, a pilot open-label study, treated patients at two clinical sites with dramatic responses. NeuroHealing initiated a Phase II, 76-patient, double blind, placebo controlled trial (http://clinicaltrials.gov/ct2/show/NCT00761228). NH001 targets a US market of $0.5 – 1 billion in peak revenues.